within Pharmacolibrary.Drugs.ATC.L;

model L04AJ05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00024333333333333333,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.345,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004266666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.878,
    k12             = 19.5,
    k21             = 19.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AJ05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Avacopan is an orally administered selective C5a receptor antagonist used for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis, such as granulomatosis with polyangiitis and microscopic polyangiitis. Approved by regulatory authorities including the FDA (under brand name Tavneos) since 2021.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults, both healthy volunteers and patients with ANCA-associated vasculitis, after oral administration of avacopan at steady state.</p><h4>References</h4><ol><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants. <i>Clinical pharmacology in drug development</i> 13(9) 1011–1023. DOI:<a href=\"https://doi.org/10.1002/cpdd.1436\">10.1002/cpdd.1436</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993035/\">https://pubmed.ncbi.nlm.nih.gov/38993035</a></p></li><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small-Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Clinical pharmacology in drug development</i> 13(9) 1000–1010. DOI:<a href=\"https://doi.org/10.1002/cpdd.1444\">10.1002/cpdd.1444</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38993026/\">https://pubmed.ncbi.nlm.nih.gov/38993026</a></p></li><li><p>Miao, S, et al., &amp; Trivedi, A (2024). Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants. <i>Clinical pharmacology in drug development</i> 13(5) 517–533. DOI:<a href=\"https://doi.org/10.1002/cpdd.1389\">10.1002/cpdd.1389</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38423992/\">https://pubmed.ncbi.nlm.nih.gov/38423992</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AJ05;
